Advertisement

Edema of Hands and Hypopigmented Lesions on Her Neck and Cheeks

  • Ana Luisa Rodríguez-Lozano
  • Marco Yamazaki-Nakashimada
Chapter

Abstract

  • Raynaud’s phenomenon is frequently a prodromal manifestation of systemic sclerosis

  • Arthralgia, weight loss, Raynaud’s phenomenon and dysphagia are red flags to consider the diagnosis of systemic sclerosis and refer the patient to a specialist

  • Myositis is frequently present as an overlapping disease with systemic sclerosis

  • Aggressive immunosuppressive therapy is indicated to prevent pulmonary, cardiovascular and gastrointestinal disease in systemic sclerosis

Keywords

Raynaud’s phenomenon Systemic sclerosis Myositis Anti-topoisomerase 1 

References

  1. 1.
    Pain CE, Constantin T, Toplak N, Moll M, Iking-Konert C, Piotto DP, Aktay Ayaz N, Nemcova D, Hoeger PH, Cutolo M, Smith V, Foeldvari I. Raynaud’s syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clin Exp Rheumatol. 2016;34(Suppl 100):200–6.PubMedGoogle Scholar
  2. 2.
    Tellier S, Bader-Meunier B, Quartier P, Belot A, Deslandre C, Kone-Paut I, Tiriau S, Jurquet AL, Rosellini D, Dheu-Bentz C, Mestrallet G, Decramer S. Initial presentation and outcome of pediatric-onset mixed connective tissue disease: a French multicenter retrospective study. Joint Bone Spine. 2016;83(3):369–71.CrossRefGoogle Scholar
  3. 3.
    Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, Lehman TJ, de Oliveira SK, Susic G, Lyskina G, Nemcova D, Sundel R, Falcini F, Girschick H, Lotito AP, Buoncompagni A, Sztajnbok F, Al-Mayouf SM, Orbàn I, Ferri C, Athreya BH, Woo P, Zulian F. Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971–8.Google Scholar
  4. 4.
    Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, Lehman TJ, de Oliveira SK, Susic G, Lyskina G, Nemcova D, Sundel R, Falcini F, Girschick H, Lotito AP, Buoncompagni A, Sztajnbok F, Al-Mayouf SM, Orban I, Ferri C, Athreya BH, Woo P, Zulian F. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 54(12):3971–8.Google Scholar
  5. 5.
    Souza EJ, Kayser C. [Nailfold capillaroscopy: relevance to the practice of rheumatology]. Rev Bras Reumatol. 2015;55(3):264–71.Google Scholar
  6. 6.
    Russo RA, Katsicas MM. Clinical characteristics of children with juvenile systemic sclerosis: follow-up of 23 patients in a single tertiary center. Pediatr Rheumatol Online J. 2007;5:6.CrossRefGoogle Scholar
  7. 7.
    Zulian FWP, Athreya BH, Laxer RM, Medsger TA, Lehman TJA, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against rheumatism provisional classification criteria for juvenile systemic sclerosis. In: Arthritis Care Res, vol. 57; 2007. p. 203–12.Google Scholar
  8. 8.
    Hatta Y, Hasegawa M, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Mod Rheumatol. 2014;24(2):377–9.CrossRefGoogle Scholar
  9. 9.
    Alba MA, Velasco C, Simeon CP, Fonollosa V, Trapiella L, Egurbide MV, Saez L, Castillo MJ, Callejas JL, Camps MT, Tolosa C, Rios JJ, Freire M, Vargas JA, Espinosa G. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine. 2014;93(2):73–81.CrossRefGoogle Scholar
  10. 10.
    Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, Steen VD, Medsger TA Jr. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004–13.PubMedGoogle Scholar
  11. 11.
    Györgyi Z, Foeldvari I, Weiser P, Szabó A, Constantin T. Recent advances in systemc scleroderma in childhood. Ann Paediatr Rheum. 2014;3:146–57.CrossRefGoogle Scholar
  12. 12.
    Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol. 2014;26(6):646–52.CrossRefGoogle Scholar
  13. 13.
    Paik JJ. Myopathy in scleroderma and in other connective tissue diseases. Curr Opin Rheumatol. 2016;28(6):631–5.CrossRefGoogle Scholar
  14. 14.
    Fotis L, Baszis KW, White AJ, French AR. Four cases of anti-PM/Scl antibody-positive juvenile overlap syndrome with features of myositis and systemic sclerosis. J Rheumatol. 2016;43(9):1768–9.CrossRefGoogle Scholar
  15. 15.
    La Torre F, Martini G, Russo R, Katsicas MM, Corona F, Calcagno G, Falcini F, Vittadello F, Zulian F. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum. 2012;64(12):4143–50.CrossRefGoogle Scholar
  16. 16.
    Zulian F, Balzarin M, Birolo C. Recent advances in the management of juvenile systemic sclerosis. Expert Rev Clin Immunol. 2017;13(4):361–9.CrossRefGoogle Scholar
  17. 17.
    Foeldvari I. Update on juvenile systemic sclerosis. Curr Rheumatol Rep. 2015;17(3):18.CrossRefGoogle Scholar
  18. 18.
    Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Muller-Ladner U. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39.CrossRefGoogle Scholar
  19. 19.
    Russell M, Sofat N. Translating autoimmune pathogenesis into targeted therapies for systemic sclerosis. In: Immunopathogenesis and immune-based therapy for selected autoimmune disorders. London: InTech; 2017. p. 97–130.Google Scholar
  20. 20.
    Sakkas LI, Bogdanos DP. Systemic sclerosis: new evidence re-enforces the role of B cells. Autoimmun Rev. 2016;15(2):155–61.CrossRefGoogle Scholar
  21. 21.
    Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med (Lond). 2015;15(Suppl 6):s58–63.CrossRefGoogle Scholar
  22. 22.
    Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol. 2017;13(5):469–82.CrossRefGoogle Scholar
  23. 23.
    Reiff A. New insights into the pathogenesis and management of juvenile systemic sclerosis. Int J Clin Rheumatol. 2015;10:97–110.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ana Luisa Rodríguez-Lozano
    • 1
  • Marco Yamazaki-Nakashimada
    • 1
  1. 1.Clinical Immunology DepartmentInstituto Nacional de PediatriaMexico CityMexico

Personalised recommendations